Comparative Pharmacology
Head-to-head clinical analysis: ALOGLIPTIN versus EMPAGLIFLOZIN LINAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOGLIPTIN versus EMPAGLIFLOZIN LINAGLIPTIN.
ALOGLIPTIN vs EMPAGLIFLOZIN; LINAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that prolongs the activity of incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
25 mg orally once daily
10 mg empagliflozin/5 mg linagliptin orally once daily.
None Documented
None Documented
Clinical Note
moderateAlogliptin + Gatifloxacin
"Alogliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateAlogliptin + Rosoxacin
"Alogliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateAlogliptin + Levofloxacin
"Alogliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateAlogliptin + Trovafloxacin
"Alogliptin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12-21 hours. This supports once-daily dosing. In patients with renal impairment, half-life is prolonged (e.g., up to 32 hours in severe impairment), necessitating dose adjustment.
Empagliflozin: ~12.4 h (supports once-daily dosing). Linagliptin: ~12 h (terminal half-life; long binding to DPP-4 allows once-daily dosing despite short half-life).
Approximately 60-71% of the dose is excreted unchanged in urine via active renal tubular secretion, with about 20% eliminated as metabolites (primarily N-demethylated and N-acetylated derivatives) in urine, and less than 2% in feces. Renal excretion is the major route.
Empagliflozin: ~54% renal (unchanged), ~41% fecal (primarily unchanged parent). Linagliptin: ~80% fecal (enterohepatic circulation), ~5% renal.
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor